NCT02269579View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Acute Myeloid Leukemia (AML)Acute Lymphoblastic Leukemia (ALL)Myelodysplastic Syndrome (MDS)
Interventions
DRUG

CPX-351

Trial Locations (5)

32610

Shands Cancer Hospital @ University of Florida, Gainesville

46237

Franciscan St. Francis Health, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

90095

Ronald Reagan UCLA Medical Center, Los Angeles

07601

John Theurer Cancer Center @ Hackensack Medical University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY